background optimal treatment patients localized carcinoma prostate controversial radiation therapy established modality management patients reports indicate results comparable achieved radical prostatectomy recently effectiveness therapy carcinoma prostate evaluated light prostatespecific antigen psa determinations methods review performed multiple publications data selected institutions large experience management carcinoma prostate survival clinical incidence local recurrence distant metastases analyzed preliminary data postirradiation psa levels factors affect outcome therapy relevant clinical trials discussed results reported differences age patients treated radical prostatectomy years irradiation years observation years identified effect surgical staging outcome irradiation significant multiple series patients clinically radiographically staged survival dfs external irradiation clinical stage t1a stage t1bc clinical stage t3 correlation identified initial psa levels probability freedom chemical failure psa elevation definitive irradiation series comprising NUMBER patients stage t1c t2 tumors dfs end point chemical failure NUMBER initial psa NUMBER psa higher NUMBER various series ranged median NUMBER years minimum NUMBER years series NUMBER NUMBER patients receiving doses cgy morbidity observed treatment planning conformal radiation therapy conventional irradiation new directions future clinical trials discussed including dose escalation studies use high linear energy transfer improve locoregional tumor control combination irradiation androgen suppression enhance local tumor control decrease distant metastasis improve survival preliminary results randomized study recently reported rtog strongly suggest use goserelin acetate flutamide decreases incidence clinical local recurrence NUMBER NUMBER patients compared control group treated irradiation NUMBER NUMBER patients enhances diseasefree survival conclusions modern approaches management patients localized carcinoma prostate irradiation effective investigators continue critically assess policies treatment develop appropriately designed prospective clinical trials define optimal management patients localized carcinoma prostate references NUMBER post treatment NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER year NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER NUMBER follow NUMBER NUMBER dimensional disease free ng ml ng ml ng ml ng ml